Navigation Links
VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions

on product sales. In May of 2006, Dr. Najarian was hired by VIVUS as part-time Principal Scientist. VIVUS is currently developing Qnexa, which is a proprietary pharmaceutical treatment that is a combination of low doses of phentermine and topiramate that is being investigated for the treatment of obesity. The abstract discussed by Dr. Najarian and published in the American Diabetes Association 2007 Scientific Sessions abstract book was not based on Qnexa. VIVUS provided funding for Dr. Najarian's analysis.

About VIVUS

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. VIVUS has three products that are positioned to enter Phase 3 clinical trials, and one product currently under NDA review by the FDA. The pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms, and on May 15, 2007, the EvaMist assets were transferred to KV Pharmaceutical Company; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE(R) is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
(Date:3/5/2015)...   ndd Medical Technologies , a leader in ... ultrasound technology, announced that its EasyOne Pro® was used ... Antonio Pulmonary Fibrosis Support Group. The clinic targeted patients ... as well as those suspected of having ILD or ... 12 square inches, EasyOne Pro provides accurate respiratory test ...
(Date:3/5/2015)... 5, 2015   AMC Health , the ... for improving the effectiveness and efficiency of healthcare ... Anazagasty and Jared Wilstead have ... President, Strategic Client Development, and Wilstead will serve ... AMC Health,s commitment to accelerating the adoption of ...
Breaking Medicine Technology:Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3
... 17, 2012 Morgan honored with The ... The National Council for Prescription Drug Programs ... throughout the pharmacy services industry, awarded Kay Morgan, Senior Vice ... for Elsevier / Gold Standard , with its highest ...
... N.C., May 17, 2012  The performance of high intensity ... invasive treatment of prostate cancer is the focus of ... Annual Meeting of the American Urological Association (AUA), in ... HIFU), a world leader in minimally invasive HIFU technologies, ...
Cached Medicine Technology:Elsevier / Gold Standard's Kay Morgan Awarded NCPCP Highest Honor 2Elsevier / Gold Standard's Kay Morgan Awarded NCPCP Highest Honor 3US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA 2US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA 3
(Date:3/5/2015)... On March 2, 2015, NBC News ... the Rise, Plastic Surgeons Say,” that comments on the ... Aesthetic Plastic Surgery and the American Society ... year-over-year doubling of surgical butt augmentations performed in 2014. ... article, this increase can be attributed to the social ...
(Date:3/5/2015)... HMP Communications Holdings , LLC ... announced today its acquisition of the Amputation ... conference designed for health care providers dedicated to ... due to vascular disorders. The 5-year-old meeting ... and CME activities across therapeutic fields such as ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... Leading nutritional supplement provider Metabolic Nutrition ... and Arnold Fitness EXPO in Columbus, Ohio ... a display booth featuring free samples of its superior ... class-leading fat burner Synedrex. The company will also be ... its top-of-the-line supplements and miniature action figures of its ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
Breaking Medicine News(10 mins):Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
... environment and energy related products and services, has ... technology effectively suppresses avian influenza viruses. // ... national university in south western Japan,Sanyo’s proprietary electrolysed ... Mist’ system was shown highly effective in suppressing ...
... biotech, the company that is known for being the sole ... known, about its intention to go public//. The company is ... per the papers filed with the Securities and Exchange Commission. ... and debates have been raging about what this science can ...
... in the British Journal of Clinical Pharmacology states that 10% ... providing morning-after pill at local pharmacies //as they have the ... Kent Primary Care Trust and the University of Bradford looked ... the medication from family planning clinics and community pharmacies. ...
... a mouse model by the Oregon Health & Science University ... of the often devastating// head and neck squamous cell cancers. ... Ph.D., and his colleagues. The results of their research breakthrough ... & Development. ,‘This is the first animal model ...
... by the researchers of Obstetricians and Gynecologists at the new ... can be tiresome and complicated. They say that this could ... of obese pregnant women it takes a longer time to ... at the annual meeting of the American College of Obstetricians ...
... will be made available to every Canadian who gets ill ... to combat a potential pandemic. ,The Minister ... A strategy is now in place to make sure everyone ... been initiated to equip the provinces to combat any public ...
Cached Medicine News:Health News:Sanyo’s Electrolysed Water Technology Effective In Suppressing Bird Fl 2Health News:Morning-After Pill At The Local Pharmacy Could Prevent Unwanted Pregnancies 2Health News:Morning-After Pill At The Local Pharmacy Could Prevent Unwanted Pregnancies 3Health News:Mouse Model Beneficial to Study of Head and Neck Cancer 2
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: